HeartBeam Outperforms Rivals in Financial Analysis

Analysts see stronger consensus rating and higher potential upside for medical tech firm compared to competitors

Apr. 16, 2026 at 9:24am

Got story updates? Submit your updates here. ›

An extreme close-up of complex medical monitoring devices, their metallic components and circuits filling the frame, conveying the technical sophistication and industrial nature of the healthcare technology sector.Detailed medical technology and infrastructure underpin the competitive landscape of the healthcare information systems industry.Malvern Today

HeartBeam (NASDAQ:BEAT), a publicly-traded company in the 'MEDICAL INFO SYS' industry, has been compared to its rivals based on factors like profitability, institutional ownership, analyst recommendations, risk, valuation, earnings and dividends. The analysis found that HeartBeam has a stronger consensus rating from analysts, higher potential upside, lower price-to-earnings ratio, and less volatile stock price compared to its peers in the industry.

Why it matters

This analysis provides investors with a comprehensive look at how HeartBeam stacks up against its competitors in the medical technology sector. The findings suggest HeartBeam may be a more favorable investment option based on its financial performance and analyst sentiment, which could impact the company's future growth and market position.

The details

The analysis found that while HeartBeam's rivals have higher revenue, the company has lower earnings and is trading at a more affordable price-to-earnings ratio. HeartBeam also has a lower beta, meaning its stock is less volatile than the overall market. In terms of ownership, only 7.8% of HeartBeam shares are held by institutional investors, compared to 43.7% for its rivals on average. However, HeartBeam beats its competitors on 7 out of 13 factors compared, including profitability metrics and analyst recommendations.

  • The analysis was published on April 16, 2026.

The players

HeartBeam

A publicly-traded company in the 'MEDICAL INFO SYS' industry.

BioTelemetry, Inc.

A remote medical technology company that provides remote cardiac monitoring, remote blood glucose monitoring, and centralized core laboratory services for clinical trials.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights HeartBeam's strong financial performance and positive analyst sentiment compared to its peers in the medical technology industry. Investors may want to take a closer look at HeartBeam as a potential investment opportunity given its favorable valuation, profitability metrics, and growth prospects.